12th December 2019 – Global Fondaparinux
Market is expected to reach USD 686.3 billion by 2024. Fondaparinux is
also termed as Fondaparinux sodium or Natural heparin pentasaccharide is an
anticoagulant medication chemically related to low molecular weight heparins.
Its trade name is Arixtra. Its molecular formula is C31H53N3O49S8 and molecular
weight is 1508.217 g/mol. Factor Xa inhibits its activity and interrupts the
blood coagulation cascade by stopping thrombus development and thrombin
formation. It is a synthetic glucopyranoside with antithrombotic activity. The
Fondaparinux Market is estimated to grow at a significant CAGR of 7.8% over the
forecast period as the scope and its applications are rising enormously across
the globe.
Growing number of hip and knee
surgeries, mounting cooperation between major players for securing the
intellectual property rights (IPRs), growing aging population and diseases like
orthopedic conditions and heart infections are documented as major factors of
Fondaparinux Market that are estimated to enhance the growth in the years to
come. However, severe side effects of drugs may restrain overall market in the
coming years. Fondaparinux Market is segmented based on product type,
application, end user, and region.
Get
a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/fondaparinux-market/request-sample
Generics drug and branded drug are the
product types that could be explored in Fondaparinux during the forecast
period. The market may be categorized based on applications like abdominal
surgery, orthopedics (knee or hip replacement), cardiovascular, and others that
could be explored in the forecast period. Home care settings, clinics,
ambulatory surgical centers, hospitals, diagnostic centers, and other end users
could be explored in Fondaparinux during the forecast period.
Globally, North America accounted for
the substantial market share of Fondaparinux and is estimated to lead the
overall market in the coming years. The reason behind the overall market growth
could be presence of key manufacturers in the region, growing awareness among
populace regarding brand and upcoming drugs, and technological enhancements as
growing aging population. The United States is a major consumer of Fondaparinux
in this region.
Instead, Europe and the Asia Pacific are
also estimated to have a positive influence on the future growth. Europe is the
second largest region with significant market share. However, Asia Pacific is
estimated to grow at fastest pace with the highest CAGR in the foremost period.
The aspects that may be ascribed to the growth comprise growing awareness among
patients and healthcare sectors and developing industries in this region. The
developing countries like India and China are the major consumers of
Fondaparinux in this region.
The key players of Fondaparinux industry
are Kaifeng Pharmaceutical, Pfizer, Inc., WisMed Pharmaceuticals, Bayer
Healthcare AG, Eisai Inc., GlaxoSmithKline Plc., Bristol-Myers Squibb Company,
BoehringerIngelheim, Aspen Holdings, Sanofi S.A., Abbott India Limited, and
Apotex. These players are concentrating on inorganic growth to sustain
themselves amongst fierce competition. As companies all over the world have to
believe that alliance with a market would permit them proportional market
existence and authority to declare the leadership position.
Get
in touch
At Million Insights, we work with the
aim to reach the highest levels of customer satisfaction. Our representatives
strive to understand diverse client requirements and cater to the same with the
most innovative and functional solutions.
For
More Information, Visit @ https://www.millioninsights.com
No comments:
Post a Comment